A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, and immunogenicity of ABP 980 and pertuzumab combined in a single infusion in healthy subjects

Bibliographic Details
Main Authors: V. Hanes, V. Chow, T. Stewart, A. Puri
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:Breast
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977621001697